Clinical trial
The Aim of This Study is to Investigate the Protective Effect of Empagliflozin on the Cardiovascular System in Diabetes Mellitus Patients
NCT03131232 is registered in ClinicalTrials.gov with RWTH Aachen University as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Aim of This Study is to Investigate the Protective Effect of Empagliflozin on the Cardiovascular System in Diabetes Mellitus Patients
- Lead sponsor
- RWTH Aachen University
- Phase
- Observational
- Overall status
- Unknown status
- Start date
- December 10, 2015
- Completion date
- December 31, 2017
- Enrollment
- 46 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.